文献速递血栓与止血

树突状细胞中HLA-II类/FVIII肽组学变异与血友病A治疗性FVIII蛋白免疫原性潜力相关

Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A.
PubMed 文献 · J Thromb Haemost · 2020-01-01

该研究利用树突状细胞-蛋白加工/呈递实验结合质谱和肽组学分析,量化了不同HLA-II类分子(DP、DQ、DR)结合的FVIII衍生肽,并比较了六种FVIII产品的免疫原性潜力。结果显示,含pdVWF的pdFVIII(Beriate)免疫原性显著低于Advate±pdVWF、Afstyla无pdVWF及Mix-rFVIII;不同rFVIII之间免疫原性有显著差异;添加pdVWF可显著降低rFVIII的免疫原性潜力。结论为不同FVIII产品的免疫原性差异及HLA-II遗传在抑制剂发展中的作用提供了肽组学层面的解释。

要点

  • 含pdVWF的pdFVIII(Beriate)免疫原性显著低于Advate±pdVWF、Afstyla无pdVWF及Mix-rFVIII。
  • 不同rFVIII产品间免疫原性潜力存在显著差异,Afstyla+pdVWF显著低于Beriate。
  • rFVIII添加pdVWF后免疫原性潜力显著低于未添加pdVWF的相同rFVIII。

核心结论

  • Beriate的免疫原性潜力显著低于Advate±pdVWF、Afstyla无pdVWF和Mix-rFVIII。
  • 不同FVIII产品免疫原性潜力显著不同,Afstyla+pdVWF显著低于Beriate,而Beriate与Xyntha+pdVWF无显著差异。
  • 添加pdVWF的rFVIII免疫原性潜力显著低于未添加pdVWF的相同rFVIII。

研究设计与样本

  • 使用正常供者和/或血友病A患者的单核细胞衍生树突状细胞,与不同FVIII产品共培养。
  • 通过质谱和肽组学分析量化HLA-II类分子(DP、DQ、DR)结合的FVIII衍生肽 counts。
  • 比较六种FVIII产品:Mix-rFVIII(Advate与四种BDD-rFVIII等摩尔混合物)、Beriate(pdFVIII+pdVWF)、Advate±pdVWF、Afstyla±pdVWF、Xyntha+pdVWF。

主要发现

  • Beriate的免疫原性潜力显著低于Advate±pdVWF、Afstyla无pdVWF和Mix-rFVIII。
  • Afstyla+pdVWF的免疫原性潜力显著低于Beriate,而Beriate与Xyntha+pdVWF无显著差异。
  • 添加pdVWF的rFVIII免疫原性潜力显著低于未添加pdVWF的相同rFVIII。

临床怎么用

  • 不同FVIII产品的免疫原性潜力存在差异,含pdVWF的产品可能免疫原性更低。
  • rFVIII联合pdVWF可能降低免疫原性潜力,支持临床选择产品时考虑VWF的作用。
  • HLA-II肽组学分析可为理解抑制剂发展的个体差异提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma-derived (pd) or recombinant (r) therapeutic factor VIII proteins (FVIIIs) are infused to arrest/prevent bleeding in patients with hemophilia A (PWHA). However, FVIIIs are neutralized if anti-FVIII-antibodies (inhibitors) develop. Accumulating evidence suggests that pdFVIIIs with von Willebrand factor (VWF) are less immunogenic than rFVIIIs and that distinct rFVIIIs are differentially immunogenic. Since inhibitor development is T-helper-cell-dependent, human leukocyte antigen (HLA)-class-II (HLAcII) molecules constitute an important early determinant. OBJECTIVES: Use dendritic cell (DC)-protein processing/presentation assays with mass-spectrometric and peptide-proteomic analyses to quantify the DP-bound, DQ-bound, and DR-bound FVIII-derived peptides in individual HLAcII repertoires and compare the immunogenic potential of six distinct FVIIIs based on their measured peptide counts. PATIENTS/METHODS: Monocyte-derived DCs from normal donors and/or PWHA were cultured with either: Mix-rFVIII, a VWF-free equimolar mixture of a full-length (FL)-rFVIII [Advate® (Takeda)] and four distinct B-domain-deleted (BDD)-rFVIIIs [Xyntha® (Pfizer), NovoEight® (Novo-Nordisk), Nuwiq® (Octapharma), and Afstyla® (CSL Behring GmBH)]; a pdFVIII + pdVWF [Beriate® (CSL Behring GmBH)]; Advate ± pdVWF; Afstyla ± pdVWF; and Xyntha + pdVWF. RESULTS: We showed that (i) Beriate had a significantly lower immunogenic potential than Advate ± pdVWF, Afstyla - pdVWF, and Mix-rFVIII; (ii) distinct FVIIIs differed significantly in their immunogenic potential in that, in addition to (i), Afstyla + pdVWF had a significantly lower immunogenic potential than Beriate, while the immunogenic potential of Beriate was not significantly different from that of Xyntha + pdVWF; and (iii) rFVIIIs with pdVWF had significantly lower immunogenic potentials than the same rFVIIIs without pdVWF. CONCLUSIONS: Our results provide HLAcII peptidomic level explanations for several important clinical observations/issues including the differential immunogenicity of distinct FVIIIs and the role of HLAcII genetics in inhibitor development.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Diego VP, Luu BW, Hofmann M, et al. Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. J Thromb Haemost. 2020. PMID: 31556206. doi:10.1111/jth.14647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。